Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + 177Lu-PNT2002 in Metastatic RCC
NCT06361810Phase 2Withdrawn
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Oct 2025
- Primary completion
- Jan 2031
- Modality
- Peptides
01
Overview
A Phase 2 trial of Lu-PNT2002 in clear cell renal cell carcinoma (ccRCC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Planned start Oct 2025; status: withdrawn.
02
Drugs
Lu-PNT2002
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06361810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06361810.